The prognosis of patients with advanced pancreatic cancer remains very poor.
Dr Yasuhiro Fujino and colleagues elucidated the prognostic factors of patients with pancreatic cancer.
The researchers also evaluated appropriate treatment with gemcitabine in these patients.
The team treated 99 consecutive patients with stage IV pancreatic cancer treated with gemcitabine.
|Pancreatic resection influenced stage IVa pancreatic cancer survival|
Prognostic variables for survival were analysed, and included sex, age, performance status, main site of the tumor.
The team also assessed tumor size, major vessel invasion, distal metastasis, resection, gemcitabine, radiation, and pathological factors.
The Cox proportional hazards model was used to determine the factors influencing the survival of patients with stage IV pancreatic cancer.
The researchers found that pancreatic resection, gemcitabine, and distant metastasis significantly influenced the survival of all these patients.
Pancreatic resection and gemcitabine were significant factors influencing the survival of patients with stage IVa pancreatic cancer.
However, the team observed that gemcitabine was the strongest factor influencing stage IVb pancreatic cancer.
Dr Fujino‘s team concluded, “Gemcitabine has a possible role for stage IV pancreatic cancer.”